Compare · INGN vs STE
INGN vs STE
Side-by-side comparison of Inogen Inc (INGN) and STERIS plc (Ireland) (STE): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both INGN and STE operate in Industrial Specialties (Health Care), so they compete in similar markets.
- STE is the larger of the two at $21.03B, about 110.2x INGN ($190.7M).
- INGN has been more active in the news (7 items in the past 4 weeks vs 3 for STE).
- STE has more recent analyst coverage (16 ratings vs 11 for INGN).
- Company
- Inogen Inc
- STERIS plc (Ireland)
- Price
- $6.97-1.97%
- $214.46-1.11%
- Market cap
- $190.7M
- $21.03B
- 1M return
- +11.08%
- -
- 1Y return
- -3.19%
- -
- Industry
- Industrial Specialties
- Industrial Specialties
- Exchange
- NASDAQ
- NYSE
- IPO
- 2014
- News (4w)
- 7
- 3
- Recent ratings
- 11
- 16
Inogen Inc
Inogen, Inc., a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The company offers Inogen One, a portable device that concentrate the air around the patient to provide a single source of supplemental oxygen; Inogen At Home stationary oxygen concentrators; Inogen Tidal Assist Ventilators, as well as related accessories. The company also rents its products directly to patients. Inogen, Inc. was incorporated in 2001 and is headquartered in Goleta, California.
STERIS plc (Ireland)
STERIS plc provides infection prevention and other procedural products and services worldwide. It operates in three segments: Healthcare, Applied Sterilization Technologies, and Life Sciences. The Healthcare segment offers cleaning chemistries and sterility assurance products; accessories for gastrointestinal (GI) procedures, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services. It also provides capital equipment installation, maintenance, upgradation, repair, and troubleshooting services; preventive maintenance programs and repair services; instrument and endoscope repair and maintenance services; and custom process improvement consulting and outsourced instrument sterile processing services. This segment offers its products and services to acute care hospitals and other healthcare settings. The Applied Sterilization Technologies segment provides contract sterilization and testing services for medical device and pharmaceutical manufacturers through a network of approximately 50 contract sterilization and laboratory facilities. The Life Sciences segment designs, manufactures and sells consumable products, such as formulated cleaning chemistries, barrier and sterility assurance products, steam and vaporized hydrogen peroxide sterilizers, and washer disinfectors. This segment also offers equipment installation, maintenance, upgradation, repair, and troubleshooting services; and preventive maintenance programs and repair services. The company is based in Dublin, Ireland.
Latest INGN
- SEC Form DEF 14A filed by Inogen Inc
- Inogen to Report First Quarter 2026 Financial Results on May 7, 2026
- SEC Form PRE 14A filed by Inogen Inc
- SEC Form 4 filed by Richardson Jason Andrew
- SEC Form 3 filed by new insider Richardson Jason Andrew
- Inogen Inc filed SEC Form 8-K: Entry into a Material Definitive Agreement, Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
- Inogen Announces the Appointment of Vafa Jamali to Board of Directors
- Inogen Announces Participation in the 25th Annual Needham Virtual Healthcare Conference
- Inogen Inc filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
- Inogen, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Latest STE
- STERIS to Host a Conference Call for Fiscal 2026 Fourth Quarter and Full Year Results on May 12, 2026
- Teleflex Announces Governance Updates
- SEC Form 8-K filed by STERIS plc (Ireland)
- Amendment: SEC Form SCHEDULE 13G/A filed by STERIS plc (Ireland)
- Director Feldmann Cynthia L exercised 3,098 units of Ordinary Shares at a strike of $152.32 and sold $734,877 worth of Ordinary Shares (3,098 units at $237.21) (SEC Form 4)
- SEC Form 144 filed by STERIS plc (Ireland)
- SEC Form 10-Q filed by STERIS plc (Ireland)
- STERIS plc (Ireland) filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- STERIS Announces Financial Results for Fiscal 2026 Third Quarter
- STERIS Announces Dividend of $0.63 per share